Literature DB >> 28012494

Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: A single-center experience.

Satoshi Ikeda1, Akimasa Sekine2, Tomohisa Baba3, Hideaki Yamakawa4, Masato Morita5, Hideya Kitamura6, Takashi Ogura7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28012494     DOI： 10.1016/j.resinv.2016.08.003

Source DB:  PubMed          Journal:  Respir Investig        ISSN： 2212-5345


× No keyword cloud information.
  9 in total

1.  Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal.

Authors:  Emanuel Raschi; Michele Fusaroli; Milo Gatti; Paolo Caraceni; Elisabetta Poluzzi; Fabrizio De Ponti
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-23

2.  Parthenolide attenuated bleomycin-induced pulmonary fibrosis via the NF-κB/Snail signaling pathway.

Authors:  Xiao-He Li; Ting Xiao; Jia-Huan Yang; Yuan Qin; Jing-Jing Gao; Hui-Juan Liu; Hong-Gang Zhou
Journal:  Respir Res       Date:  2018-06-05

3.  Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.

Authors:  Tang-Hsiu Huang; Chin-Wei Kuo; Chian-Wei Chen; Yau-Lin Tseng; Chao-Liang Wu; Sheng-Hsiang Lin
Journal:  BMC Pulm Med       Date:  2021-05-15       Impact factor: 3.317

4.  Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Kazutaka Takehara; Yasuhiko Koga; Yoshimasa Hachisu; Mitsuyoshi Utsugi; Yuri Sawada; Yasuyuki Saito; Seishi Yoshimi; Masakiyo Yatomi; Yuki Shin; Ikuo Wakamatsu; Kazue Umetsu; Shunichi Kouno; Junichi Nakagawa; Noriaki Sunaga; Toshitaka Maeno; Takeshi Hisada
Journal:  Cells       Date:  2022-01-02       Impact factor: 6.600

5.  The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study.

Authors:  Masaki Dobashi; Hisashi Tanaka; Kageaki Taima; Masamichi Itoga; Yoshiko Ishioka; Toshihiro Shiratori; Fumihiko Okumura; Chiori Tabe; Yoshihito Tanaka; Takeshi Morimoto; Yukihiro Hasegawa; Hideo Yasugahira; Koichi Okudera; Shingo Takanashi; Sadatomo Tasaka
Journal:  SAGE Open Med       Date:  2021-06-06

Review 6.  Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.

Authors:  Amy Hajari Case; Peace Johnson
Journal:  BMJ Open Respir Res       Date:  2017-06-28

7.  Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis.

Authors:  Satoshi Ikeda; Akimasa Sekine; Tomohisa Baba; Yumie Yamanaka; Shinko Sadoyama; Hideaki Yamakawa; Tsuneyuki Oda; Ryo Okuda; Hideya Kitamura; Koji Okudela; Tae Iwasawa; Kenichi Ohashi; Tamiko Takemura; Takashi Ogura
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

8.  Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study.

Authors:  Mitsuhiro Abe; Kenji Tsushima; Masashi Sakayori; Kenichi Suzuki; Jun Ikari; Jiro Terada; Koichiro Tatsumi
Journal:  Drug Des Devel Ther       Date:  2018-10-09       Impact factor: 4.162

9.  Imrecoxib Inhibits Paraquat-Induced Pulmonary Fibrosis through the NF-κB/Snail Signaling Pathway.

Authors:  Haihao Jin
Journal:  Comput Math Methods Med       Date:  2020-10-13       Impact factor: 2.238
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.